Incyte nabs approval of topical ruxolitinib in atopic dermatitis, but gets slapped with JAK warning

Incyte has made a pretty penny with its JAK inhibitor ruxolitinib over the years, but on Tuesday the drug crossed a new threshold.

The FDA approved a topical formulation of the drug for mild-to-moderate atopic dermatitis, Incyte announced Tuesday afternoon, giving the Wilmington, DE-based company a new arrow in its ruxolitinib quiver. The drug, which will be marketed as Opzelura, is the first topical JAK inhibitor approved in the US and is indicated for AD patients aged 12 and up who struggle to control their disease on other prescription creams.